Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
There could be more catalysts for the biotech over the next 18 months.
Viking Therapeutics stock surged by 36% after unveiling promising data from a weight-loss drug clinical trial, sparking questions about the company's potential. While Eli Lilly and Novo Nordisk maintain their leading positions in the weight loss drug market, Viking Therapeutics (NASDAQ: VKTX) is making noteworthy progress in clinical stages.
Recently, the clinical-stage biotech experienced a significant rise in its stock price, jumping over 30% in a single day. To understand the implications of these results, it is essential to delve into the mechanism behind GLP-1-based weight loss medicines. These medications function by imitating naturally occurring hormones like GLP-1, which promote feelings of fullness. This leads patients to consume fewer calories, ultimately contributing to weight loss.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
